SCHEMBL17446917

SCHEMBL17446917

C=C1C[C@@H](C)C(c2ccc(/C=C/C)cc2)=NN1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PDE3B Q13370 17/20 0.39
▸ PDE3A Q14432 17/20 0.39
▸ PDE4A P27815 4/20 0.36
▸ PDE4B Q07343 4/20 0.36
▸ PDE4C Q08493 4/20 0.36
▸ PDE4D Q08499 4/20 0.36
▸ TNNC1 P63316 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ PDE2A O00408 1/20 0.33
▸ PDE1A P54750 1/20 0.33
▸ PDE1B Q01064 1/20 0.33
▸ PDE1C Q14123 1/20 0.33
▸ HRH3 Q9Y5N1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16157194 0.83 PDE3B (0.57) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL16156960 0.83 PDE3B (0.57) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL17446955 0.80 PDE3B (0.43) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL17446918 0.79 PDE3B (0.42) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL17446937 0.79 PDE3B (0.42) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL17446924 0.79 PDE3B (0.48) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL17446949 0.79 GPR119 (0.42) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL17446932 0.77 PDE3B (0.39) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL17446920 0.75 PDE3B (0.40) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL17446942 0.73 PDE3B (0.44) PDE3BPDE3APDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9890127-B2 Compounds and compositions for the treatment of cancer THE BROAD INSTITUTE, INC. (US) 2018-02-13 — — US disclosed
US-20160016913-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER THE BROAD INSTITUTE, INC. (US) 2016-01-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160016913-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER TP53, RB1, CDK4 PDE3B 2667/4885PDE3A 2661/4885PDE4A 3343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback